On January 6, 2014, Neurocrine Biosciences, Inc. (NBIX) announced results from the Phase 2b KINECT-2 study with small molecule VMAT2 inhibitor, NBI-98854, showed statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms. The news is a pleasant surprise to Neurocrine investors after the mixed results of the KINECT-1 study in September 2013. The key differences between these two trials include dose titration and underlying disorder. Below we provide a quick background on the drug, a summary of the data from KINECT-2, a rehash of the KINECT-1 data, post some thoughts on what the future holds with respect to KINECT-3, outline timelines for moving NBI-98854 forward, and conclude with a valuation for the shares...
Only subscribers can access this article, which is part of the PRO research library covering 3,583 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: